Applicability of a Blood–Brain Barrier Specific Artificial Membrane Permeability Assay at the Early Stage of Natural Product-Based CNS Drug Discovery

2013 ◽  
Vol 76 (4) ◽  
pp. 655-663 ◽  
Author(s):  
Árpád Könczöl ◽  
Judit Müller ◽  
Emília Földes ◽  
Zoltán Béni ◽  
Krisztina Végh ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Natural Product ◽  
Membrane Permeability ◽  
Blood Brain Barrier ◽  
Early Stage ◽  
Brain Barrier ◽  
Artificial Membrane ◽  
Blood Brain ◽  
Permeability Assay

High throughput artificial membrane permeability assay for blood–brain barrier

2003 ◽  
Vol 38 (3) ◽  
pp. 223-232 ◽  
Author(s):  
Li Di ◽  
Edward H Kerns ◽  
Kristi Fan ◽  
Oliver J McConnell ◽  
Guy T Carter
Keyword(s):  
Membrane Permeability ◽  
Blood Brain Barrier ◽  
High Throughput ◽  
Brain Barrier ◽  
Artificial Membrane ◽  
Blood Brain ◽  
Permeability Assay

scholarly journals Miniaturization and Automation of a Human In Vitro Blood–Brain Barrier Model for the High-Throughput Screening of Compounds in the Early Stage of Drug Discovery

Pharmaceutics ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 892
Author(s):  
Elisa L. J. Moya ◽  
Elodie Vandenhaute ◽  
Eleonora Rizzi ◽  
Marie-Christine Boucau ◽  
Johan Hachani ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Blood Brain Barrier ◽  
Early Stage ◽  
Molecular Transport ◽  
Brain Barrier ◽  
Blood Brain ◽  
Cns Drugs ◽  
The Impact ◽  
The Brain

Central nervous system (CNS) diseases are one of the top causes of death worldwide. As there is a difficulty of drug penetration into the brain due to the blood–brain barrier (BBB), many CNS drugs treatments fail in clinical trials. Hence, there is a need to develop effective CNS drugs following strategies for delivery to the brain by better selecting them as early as possible during the drug discovery process. The use of in vitro BBB models has proved useful to evaluate the impact of drugs/compounds toxicity, BBB permeation rates and molecular transport mechanisms within the brain cells in academic research and early-stage drug discovery. However, these studies that require biological material (animal brain or human cells) are time-consuming and involve costly amounts of materials and plastic wastes due to the format of the models. Hence, to adapt to the high yields needed in early-stage drug discoveries for compound screenings, a patented well-established human in vitro BBB model was miniaturized and automated into a 96-well format. This replicate met all the BBB model reliability criteria to get predictive results, allowing a significant reduction in biological materials, waste and a higher screening capacity for being extensively used during early-stage drug discovery studies.

Case study: adapting in vitro blood–brain barrier models for use in early-stage drug discovery

2012 ◽  
Vol 17 (7-8) ◽  
pp. 285-290 ◽  
Author(s):  
Elodie Vandenhaute ◽  
Emmanuel Sevin ◽  
Dorothée Hallier-Vanuxeem ◽  
Marie-Pierre Dehouck ◽  
Roméo Cecchelli
Keyword(s):  
Drug Discovery ◽  
Blood Brain Barrier ◽  
Early Stage ◽  
Brain Barrier ◽  
Blood Brain

scholarly journals Human iPSC‐Derived Blood‐Brain Barrier Models: Valuable Tools for Preclinical Drug Discovery and Development?

2020 ◽  
Vol 55 (1) ◽  
Author(s):  
Antje Appelt‐Menzel ◽  
Sabrina Oerter ◽  
Sanjana Mathew ◽  
Undine Haferkamp ◽  
Carla Hartmann ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Drug Discovery And Development ◽  
Blood Brain ◽  
Human Ipsc
Sign in / Sign up

Export Citation Format

Share Document